A Population Pharmacokinetic Model Incorporating Saturable Pharmacokinetics and Autoinduction for High Rifampicin Doses

Accumulating evidence suggests that increasing doses of rifampicin may shorten tuberculosis treatment. The PanACEA HIGHRIF1 trial assessed safety, pharmacokinetics, and antimycobacterial activity of rifampicin at doses up to 40 mg/kg. Eighty‐three pulmonary tuberculosis patients received 10, 20, 25,...

Descripción completa

Detalles Bibliográficos
Autores principales: Svensson, Robin J., Aarnoutse, Rob E., Diacon, Andreas H., Dawson, Rodney, Gillespie, Stephen H., Boeree, Martin J., Simonsson, Ulrika S.H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5888114/
https://www.ncbi.nlm.nih.gov/pubmed/28653479
http://dx.doi.org/10.1002/cpt.778

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5888114/
https://www.ncbi.nlm.nih.gov/pubmed/28653479
http://dx.doi.org/10.1002/cpt.778

Ejemplares similares